Physician

Transcarent Selects The Clinic by Cleveland Clinic to Provide Members Access to World-Renowned Specialists for Expert Second Opinions

Retrieved on: 
Thursday, January 12, 2023

Transcarent Members can easily leverage Cleveland Clinic’s world-renowned specialists for a personalized care evaluation and coordinated follow-up as a Transcarent benefit, all in one seamless experience.

Key Points: 
  • Transcarent Members can easily leverage Cleveland Clinic’s world-renowned specialists for a personalized care evaluation and coordinated follow-up as a Transcarent benefit, all in one seamless experience.
  • By partnering with The Clinic by Cleveland Clinic, Transcarent Members will have virtual access to Cleveland Clinic’s 3,500 world-renowned expert specialists.
  • Through The Clinic’s Virtual Expert Second Opinions program, an expert physician thoroughly reviews a Member’s diagnosis and/or treatment plan and provides a personalized second opinion.
  • “With convenient, virtual access to world-renowned specialists, Transcarent Members will receive high-value care regardless of income, zip code, or shift schedule.

Alpine Investors Announces Partnership with Leading Revenue Cycle Management Provider, Medusind

Retrieved on: 
Thursday, January 12, 2023

Today, Alpine Investors , a people-driven private equity firm, announced that it has made an investment in Medusind , a leading provider of revenue cycle management services to the healthcare industry.

Key Points: 
  • Today, Alpine Investors , a people-driven private equity firm, announced that it has made an investment in Medusind , a leading provider of revenue cycle management services to the healthcare industry.
  • Jose Rivero, an Alpine CEO-in-Residence and part of the firm’s PeopleFirst program, has assumed the role of CEO of Medusind.
  • Founded in 2002, Medusind provides deep expertise and powerful revenue cycle management solutions to dental, anesthesia, pathology, emergency, surgery, radiology, and other specialties.
  • “On behalf of everyone at Alpine, we are excited to collaborate with Jose and the Medusind management team to continue to advance its leadership position as one of the top revenue cycle management companies in the country,” said Graham Weaver, CEO and Founding Partner at Alpine Investors.

Renaissance Physicians Partners Launches Initiative to Acquire Independent Houston Providers

Retrieved on: 
Thursday, January 12, 2023

Renaissance Physicians Partners (RPP), a physician-led organization, announced today that it plans to acquire independent physician practices and offer them a unique way to maintain their autonomy while providing financial stability and increasing provider satisfaction.

Key Points: 
  • Renaissance Physicians Partners (RPP), a physician-led organization, announced today that it plans to acquire independent physician practices and offer them a unique way to maintain their autonomy while providing financial stability and increasing provider satisfaction.
  • With the support of Capital Group for Better Health, RPP will acquire physician practices and provide administrative and operational support, and assist in optimizing workflows and systems based on provider experience.
  • “Our primary focus is to help physicians continue to provide excellent care for residents in the Houston area while operating a financially stable business,” said Kevin Horn, MD, chairman of RPP.
  • Practices owned by RPP will have the opportunity to participate in payer contracts through Renaissance Physicians Organization network, which has a collective network of 1,400 primary care physicians and specialists who are serving the needs of approximately 45,000 patients in Houston.

Cardiovascular Systems, Inc. Enrolls First Patient in Japan for Kaizen Clinical Study

Retrieved on: 
Wednesday, January 11, 2023

The first KAIZEN patient was enrolled by Tatsuya Nakama, M.D., Vice Director, Department of Cardiology, Tokyo Bay Urayasu Ichikawa Medical Center.

Key Points: 
  • The first KAIZEN patient was enrolled by Tatsuya Nakama, M.D., Vice Director, Department of Cardiology, Tokyo Bay Urayasu Ichikawa Medical Center.
  • Dr. Nakama said, “I felt that the Diamondback 360© Peripheral OAS offered both effective treatment and ease of use.
  • OAS has demonstrated safety and efficacy in the U.S. population and this study is designed to confirm this in Japan.
  • I believe the Diamondback 360© Peripheral OAS has great potential for this underserved patient population, and I look forward to evaluating it in Japan.

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2023: Rising Healthcare Expenditure Fuels Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023

The adalimumab, infliximab and etanercept biosimilars market is segmented by product into adalimumab biosimilars, infliximab biosimilars, and Cipleumab.

Key Points: 
  • The adalimumab, infliximab and etanercept biosimilars market is segmented by product into adalimumab biosimilars, infliximab biosimilars, and Cipleumab.
  • The adalimumab biosimilars market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by product, accounting for 39.33% of the total in 2021.
  • The global adalimumab, infliximab and etanercept biosimilars market is concentrated, with a small number of large players in the market.
  • The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by product will arise in the adalimumab biosimilars market segment, which will gain $1,165.5 million of global annual sales by 2026.

Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance

Retrieved on: 
Wednesday, January 11, 2023

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fiscal year ended December 31, 2022 and issued fiscal year 2023 revenue guidance.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fiscal year ended December 31, 2022 and issued fiscal year 2023 revenue guidance.
  • “This quarter’s record revenue result reflects the growing demand for our best-in-class incontinence products,” said Raymond W. Cohen, chief executive officer of Axonics.
  • Sacral neuromodulation revenue is expected to be in the range of $222.0 million, an increase of 41% compared to $157.6 million in fiscal year 2021.
  • Total company net revenue is expected to be $342 million, which is based on sacral neuromodulation and Bulkamid revenue each growing 25% compared to fiscal year 2022.

Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer

Retrieved on: 
Wednesday, January 11, 2023

The study titled, “Early Experience with UGN-101 for the Treatment of Upper Tract Urothelial Cancer – A Multi-Center Evaluation of Practice Patterns and Outcomes,” is published in Urologic Oncology: Seminars and Original Investigations.

Key Points: 
  • The study titled, “Early Experience with UGN-101 for the Treatment of Upper Tract Urothelial Cancer – A Multi-Center Evaluation of Practice Patterns and Outcomes,” is published in Urologic Oncology: Seminars and Original Investigations.
  • The authors describe several trends in JELMYTO use that differ from the pivotal Olympus study that led to drug approval.
  • JELMYTO is indicated for the treatment of adult patients with low-grade upper tract urothelial cancer (LG-UTUC).
  • Almost half of the patients in the review were treated by antegrade administration of JELMYTO through a nephrostomy tube.

Signify Health and Prospect Medical Holdings Collaborate to Deliver Coordinated, High-Quality Care

Retrieved on: 
Wednesday, January 11, 2023

Prospect, an experienced MSSP participant, will maximize its potential for improving quality of care and patient outcomes by moving into the Enhanced MSSP track.

Key Points: 
  • Prospect, an experienced MSSP participant, will maximize its potential for improving quality of care and patient outcomes by moving into the Enhanced MSSP track.
  • Signify Health will support Prospect facilities with data-driven, tailored population health roadmaps and economically aligned pricing to help its providers manage their MSSP ACO risk, reduce costs and achieve greater quality incentives for their efforts.
  • The strategic collaboration will help Prospect improve health outcomes for patients who receive care in its hospitals, which serve diverse and underserved communities across the state.
  • With this acquisition, Signify Health supports one of the largest networks of at-risk providers and offers one comprehensive platform to manage total cost of care.

The IMA Group Acquires Clinical Trials of America

Retrieved on: 
Wednesday, January 11, 2023

The IMA Group (IMA) today announced it had completed the acquisition of Clinical Trials of America (CTA), a multi-therapeutic clinical trials company that brings to IMA four new independent and six embedded site locations in Louisiana and North Carolina.

Key Points: 
  • The IMA Group (IMA) today announced it had completed the acquisition of Clinical Trials of America (CTA), a multi-therapeutic clinical trials company that brings to IMA four new independent and six embedded site locations in Louisiana and North Carolina.
  • CTA's integrated physician practice research model and focus on recruiting diverse patients ideally fits with IMA Clinical Research's vision and growth trajectory."
  • Dr. Andrews joins the IMA Clinical Research team as Senior Regional Director of Operations.
  • He also will assist with new site development and principal investigator onboarding for IMA Clinical Research.

Exo® Wins 2023 BIG Innovation Award for Exo Works™

Retrieved on: 
Wednesday, January 11, 2023

Exo (pronounced “echo”), a pioneering medical imaging software and devices company, today announced it has been named a winner in the 2023 BIG Innovation Awards , presented by the Business Intelligence Group.

Key Points: 
  • Exo (pronounced “echo”), a pioneering medical imaging software and devices company, today announced it has been named a winner in the 2023 BIG Innovation Awards , presented by the Business Intelligence Group.
  • Exo launched Exo Works in March 2022 to make it easy to address common ultrasound challenges.
  • We designed Exo Works with physicians and patients at the forefront, so that exam documentation is now a breeze,” said Sandeep Akkaraju, CEO and co-founder of Exo.
  • “The entire Exo team is honored to be recognized by the BIG Innovation Awards as we continue our mission to bring medical imaging everywhere.”
    To learn more about Exo Works, click here .